R&D Incentives Awarded By FDA, Not Patents, Suggested In Health Affairs
Executive Summary
Policy efforts to balance incentives for research and development with free-market competition may be more successful if they focus on FDA regulation rather than the patent system, an article in the September/ October issue of Health Affairs suggests.
You may also be interested in...
NPC Study Says New Drugs Offset Nondrug Spending: Will CBO Agree?
A National Pharmaceutical Council-funded analysis of the value of newer medicines will give brand name pharmaceutical companies additional evidence to argue that the cost of a Medicare prescription drug benefit may be offset by savings in other health spending.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials